FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Domestic FDA Inspections to Begin 7/20
07/10/2020
 
 
TXT House Appropriators Approve $41 million Boost
07/07/2020
 
 
TXT Reject Covid Vaccine Challenge Trials: Public Citizen
07/07/2020
 
 
TXT REMS Modification, Revision Guidance
07/07/2020
 
 
TXT Many Drug Firms Up Prices During Pandemic: Analysis
07/08/2020
 
 
TXT Court Says it Can Hear Paragraph IV Conversion Case
07/08/2020
 
 
TXT Stakeholder Participation Sought for PDUFA Reauthorization
07/07/2020
 
 
TXT 4 Cancer Clinical Trial Eligibility Criteria Guides
07/10/2020
 
 
TXT WLF Wants Access to PGx Information
07/09/2020
 
 
TXT Comments on AI in Radiological Imaging
07/09/2020
 
 
TXT FDA Posts Interim Essure Study Results
07/08/2020
 
 
TXT Ionogen Selling Unapproved Covid Drug: FDA
07/08/2020
 
 
TXT QS, MDR Violations at Luminex Corp.
07/07/2020
 
 
TXT Since Our Last Issue ...
07/12/2020
 
 
TXT Product Approval Summaries
07/12/2020
 
 
TXT Latest Federal Register Notices
07/12/2020
 
 
TXT Draft Guide on Peripheral Vascular Atherectomy Devices
07/10/2020
 
 
TXT Panel to Discuss Mallinckrodt’s NDA for Terlipressin
07/09/2020
 
 
TXT Finalize Fecal Transplantation Guidance: Petition
07/08/2020
 
 
TXT Merck, Eisai Get ‘Complete Response’ on Combo Therapy
07/08/2020
 
 
TXT CGMP, Other Issues at Washington Homeopathic
07/08/2020
 
 
TXT Biogen Completes Alzheimer’s Treatment BLA
07/08/2020
 
 
TXT CGMP Deviations at Vega Life Sciences
07/07/2020
 
 
TXT Arrow Recalls Intra-Aortic Balloon Pumps
07/07/2020
 
 
TXT Latest FDA Warning Letters
07/07/2020
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving